1 |
BECK A, WAGNER-ROUSSET E, AYOUB D, et al.. Characterization of therapeutic antibodies and related products[J]. Anal. Chem., 2013, 85(2): 715-736.
|
2 |
张忠兵,韦薇,罗建辉.生物类似药糖基化相似性评价中的审评思考[J].中国新药杂志,2020,29(21):2476-2480.
|
3 |
周爱萍.生物治疗药物和生物类似药研究进展[J].中国新药杂志,2017,26(3):296-299.
|
4 |
HELENE K, MURALIDHARAN M, SCHNEIDER Z, et al.. Antibodies to watch in 2020[J]. MAbs, 2020, 12(1): 1-8.
|
5 |
FDA. New Drug Therapy Approvals 2019 [EB/OL]. [2020-01-06]. .
|
6 |
WANG W. Instability, stabilization, and formulation of liquid protein pharmaceuticals[J]. Int. J. Pharm., 1999, 185(2): 129-188.
|
7 |
ALEXIS O, JOSEB F, MATIAS L. New trends in analysis of biopharmaceutical products[J]. Curr. Pharm. Anal., 2007, 3(4):230-248.
|
8 |
DHAMA K, MUNJAL A, HMN I. Recent advances and novel strategies for the development of biomedical therapeutics: state-of-the-art and future perspectives[J]. Int. J. Pharm., 2017, 13(7): 929-933.
|
9 |
GAVINA J, BRITZ-MCKIBBIN P. Protein unfolding and conformational studies by capillary electrophoresis[J]. Curr. Anal. Chem., 2007, 3(1): 17-31.
|
10 |
MCAVAN B S, BOWSHER L A, Powell T, et al.. Raman spectroscopy to monitor post-translational modifications and degradation in monoclonal antibody therapeutics[J]. Anal. Chem., 2020, 92(15): 10381-10389.
|
11 |
DIDIER C, VERONIQUE H, WOINET B, et al.. A spray freeze dried micropellet based formulation proof-of-concept for a yellow fever vaccine candidate[J]. Eur. J. Pharm. Biopharm., 2019, 142: 334-343.
|
12 |
DIDER C. Accurate prediction of vaccine stability under real storage conditions and during temperature excursions[J]. Eur. J. Pharm. Biopharm., 2018, 125: 76-84.
|
13 |
HALLEY J, CHOU Y R, CICCHINO C, et al.. An Industry perspective on forced degradation studies of biopharmaceuticals: survey outcome and recommendations[J]. J. Pharm., 2019, 109(1): 6-21.
|
14 |
HASELLBERG R, BRINKS V, HAWE A, et al.. Capillaryelectrophoresis-mass spectrometry using noncovalently coated capillariesfor the analysis of biopharmaceuticals[J]. Anal. Bioanal. Chem., 2011, 400: 295-303.
|
15 |
LIM A, DOYLE B L, KELLY G M, et al.. Characterization of a cathepsin D protease from CHO cell-free medium and mitigation of its impact on the stability of a recombinant therapeutic protein[J]. Biotechnol. Prog., 2018, 34(1): 120-129.
|
16 |
DOVGAN T, GOLGHALYANI V, ZURLO F, et al.. Targeted CHO cell engineering approaches can reduce HCP-related enzymatic degradation and improve mAb product quality[J]. Biotechnol. Bioeng., 2021, 118: 3821-3831.
|
17 |
PACEA L, WONG R L, ZHANG Y T, et al.. Asparagine deamidation dependence on buffer type, pH, and temperature[J]. J. Pharm., 2013, 102(6): 1712-1723.
|
18 |
PERICO N, PURTELL J, DILLON T M, et al.. Conformational implications of an inversed pH-dependent antibody aggregation[J]. J. Pharm., 2009, 98(9): 3031-3042.
|
19 |
PATEL J, KOTHARI R, TUNGA R, et al.. Stability considerations for biopharmaceuticals, part 1: overview of protein and peptide degradation pathways[J]. Bioprocess Int., 2011, 9(1): 20-31.
|
20 |
SINGH S K, MISHRA A, GOEL G, et al.. Modulation of granulocyte colony stimulating factor conformation and receptor binding by methionine oxidation[J]. Protein, 2020, 86(1): 1-13.
|
21 |
GRAF T, ABSTIENS K, WEDEKIND F, et al.. Controlled polysorbate 20 hydrolysis — a new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time[J]. Eur. J. Pharm. Biopharm., 2020, 152: 318-326.
|
22 |
LIU H, GAZZ-BULSECO G, ZHOU L. Mass spectrometry analysis of photo-induced methionine oxidation of a recombinant human monoclonal antibody[J]. J. Am. Soc. Mass Spectrom., 2009, 20(3): 525-528.
|
23 |
SCHEICH C. Photo-degradation of therapeutic proteins: mechanistic aspects[J]. Pharm. Res., 2020, 37(3): 2763-2768.
|
24 |
REID LO, VIGNONI M, MARTINS-FROMENT N, et al.. Photochemistry of tyrosine dimer: when an oxidative lesionof proteins is able to photoinduce further damage[J]. Photochem. Photobiol. Sci., 2019, 18(7): 1732-1741.
|
25 |
HEMMLER D, GONSIOR M, POWERS L C, et al.. Simulated sunlight selectively modifies Maillard reaction products in a wide array of chemical reactions[J].Chemistry, 2019, 25(57): 13208-13217.
|
26 |
KAUR H, KAMALOV M, BRIMBLE M A. Chemical synthesis of peptidescontaining site-specific advanced glycation endproducts[J]. Acc. Chem. Res., 2016, 49(10): 2199-2208.
|
27 |
JACOBITZ A W, DYLSTRA A B, SPAHR C, et al.. Effects of buffer composition on site-specific glycation of lysine residues in monoclonal antibodies[J]. J. Pharm., 2019, 109(1): 1606-1615.
|
28 |
LAMORE S D, AZIMIAN S, HORN D, et al.. The malondialdehyde-derived fluorophore DHP-lysineis a potent sensitizer of UVA-induced photooxidative stress inhuman skin cells[J]. J. Photochem. Photobiol. B, 2010, 101(3): 251-264.
|
29 |
LATYPOV R F, HOGAN S, LAU H, et al.. Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc[J]. J. Biolog. Chem., 2011, 287(2): 1381-1396.
|
30 |
HAUPTMANN A, PODGOREK K, KUZMAN D, et al.. Impact of buffer, protein concentration and sucrose addition on the aggregation and particle formation during freezing and thawing[J]. Pharm. Res., 2018, 35(5): 101-117.
|
31 |
KEVIN P, KEN T, CHAD E, et al.. Solution pH jump during antibody and Fc-fusion protein thaw leads to increased aggregation[J]. J. Pharm. Anal., 2018, 8(5): 302-306.
|
32 |
JUN Z, CHRISTOPHER W, FENG H, et al.. Structural changes and aggregation mechanisms of two different dimers of an IgG2 monoclonal antibody[J]. Biochemistry, 2018, 57(37): 5466-5479.
|
33 |
BEE J S, STEVENSON J L, MEHTA B, et al.. Response of a concentrated monoclonal antibody formulation to high shear[J]. Biotechnol. Bioeng., 2009, 103(5): 936-943.
|
34 |
WANG W, NEMA S, TEAGARDEN D. Protein aggregation-pathways and influencing factors[J]. Int. J. Pharm., 2010, 390(2): 89-99.
|
35 |
MAA Y F, HSU C C. Effect of high shear on proteins[J]. Biotechnol. Bioeng., 2015, 51(4): 458-465.
|
36 |
MARCH D, BIANCO V, FRANZESE G. Protein unfolding and aggregation near a hydrophobic interface[J]. Polymers, 2021, 13(1): 156-170.
|
37 |
FLEISCHMAN M L, CHUNG J, PAUL E P, et al.. Shipping induced aggregation in therapeutic antibodies: utilization of a scale down model to assess degradation in mAbs[J]. J. Pharm. Sci., 2016, 106(4): 994-1000.
|
38 |
SSK A, SMP B, RS C, et al.. Key factors governing the reconstitution time of high concentration lyophilized protein formulations[J]. Eur. J. Pharm. Biopharm., 2021, 165: 361-373.
|
39 |
JEAN-RENE A, RODRIGUES M A, SERGUEI T, et al.. Freezing of biologicals revisited: scale, stability, excipients, and degradation stresses[J]. J. Pharm. Sci., 2020, 109(1): 44-61.
|
40 |
AL-HUSSEIN A, GIESELER H. Investigation of histidine stabilizing effects on LDH during freeze-drying[J]. J. Pharm. Sci., 2013, 102(3): 813-826.
|
41 |
SEIFERT I, FRIESS W. Improvement of arginine hydrochloride based antibody lyophilisates[J]. Int. Pharm., 2020, 589: 118589-118688.
|
42 |
ARAKAWA T, PRESTRELSKI S J, KENNEY W C, et al.. Factors affecting short-term and long-term stabilities of proteins[J]. Adv. Drug Deliv. Rev., 2001, 46: 307-326.
|
43 |
王静,赵文静,胡春梅,等.蛋白/多肽类药物脂质体的研究进展[J].化工技术与开发,2017,46(8):32-36.
|
44 |
HE P, TANG Z, LIN L, et al.. Novel biodegradable and pH-sensitive poly (ester amide) microspheres for oral insulin delivery[J]. Macromol. Biosci., 2012, 12(4): 547-556.
|
45 |
YU Y, SHAO Y, ZHOU M, et al.. Polyethylene glycol-derived polyelectrolyte-protein nanoclusters for protein drug delivery[J]. RSC Adv., 2021, 46: 521-532.
|
46 |
Houser J, KOSOUROVA J, KUBICKOVA M, et al.. Development of 48-condition buffer screen for protein stability assessment[J]. Biophys. Struc. Mech., 2021, 50: 461-471.
|
47 |
RABE M, KERTH A, BLUME A, et al.. Albumin displacement at the air-water interface by Tween (Polysorbate) surfactants[J]. Eur. Biophys. J., 2020, 49: 533-547.
|
48 |
EBEL C, EISENBERQ H, GHIRLANDO R. Probing protein-sugar inter⁃actions[J]. Biophys. J., 2000, 78(1): 385-393.
|
49 |
PALMER B, ANGUS K, TAYLOR L, et al.. Design of stability at ex⁃treme alkaline pH in streptococcal protein G [J]. J. Biotechnol., 2008, 134(3): 222-230.
|
50 |
WALTHER R, ZELIKIN A N. Chemical (neo) glycosylation of biological drugs[J]. Adv. Drug Deliv. Rev., 2021, 171: 62-76.
|
51 |
OYAMA K, OHKURI T, OCHI J, et al.. Abolition of aggregation of CH2 domain of human IgG1 when combining glycosylation and protein stabilization[J]. Biochem. Biophys. Res. Commun., 2021, 558: 114-119.
|
52 |
KANAZAWA I, NOSTU M, TANAKA K, et al.. An open-label longitudinal study on the efficacy of switching from insulin glargine or detemir to degludec in type 2 diabetes mellitus[J]. Int. Med., 2015, 54(13): 1591-1598.
|
53 |
ZHENG J, MA B, TSAI C J, et al.. Structural stability and dynamics of an amyloid-forming peptide GNNQQNY from the yeast prion Sup-35[J]. Biophys. J., 2006, 91(3): 824-833.
|